EGFR and neoplasm: The therapeutic effect of the nanoengagers was evaluated in multiple tumor models, including EGFR expressing mouse breast cancer A431, human breast cancer MB468 xenograft models, and human colorectal adenocarcinoma EGFP+ HT‐29 and lymphoma model EGFP‐Raji dual xenograft models in T cell‐deficient mice (Figure 13c).